Kimura Motoko Y, Hayashizaki Koji, Tokoyoda Koji, Takamura Shiki, Motohashi Shinichiro, Nakayama Toshinori
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Department of Osteoimmunology, German Rheumatism Research Centre (DRFZ) Berlin, Berlin, Germany.
Immunol Rev. 2017 Jul;278(1):87-100. doi: 10.1111/imr.12559.
CD69 has been known as an early activation marker of lymphocytes; whereas, recent studies demonstrate that CD69 also has critical functions in immune responses. Early studies using human samples revealed the involvement of CD69 in various inflammatory diseases including asthma. Moreover, murine disease models using Cd69 mice and/or anti-CD69 antibody (Ab) treatment have revealed crucial roles for CD69 in inflammatory responses. However, it had not been clear how the CD69 molecule contributes to the pathogenesis of inflammatory diseases. We recently elucidated a novel mechanism, in which the interaction between CD69 and its ligands, myosin light chain 9, 12a and 12b (Myl9/12) play a critical role in the recruitment of activated T cells into the inflammatory lung. In this review, we first summarize CD69 function based on its structure and then introduce the evidence for the involvement of CD69 in human diseases and murine disease models. Then, we will describe how we discovered CD69 ligands, Myl9 and Myl12, and how the CD69-Myl9 system regulates airway inflammation. Finally, we will discuss possible therapeutic usages of the blocking Ab to the CD69-Myl9 system.
CD69一直被认为是淋巴细胞的早期激活标志物;然而,最近的研究表明,CD69在免疫反应中也具有关键作用。早期使用人类样本的研究揭示了CD69参与包括哮喘在内的各种炎症性疾病。此外,使用Cd69基因敲除小鼠和/或抗CD69抗体(Ab)治疗的小鼠疾病模型揭示了CD69在炎症反应中的关键作用。然而,CD69分子如何促成炎症性疾病的发病机制尚不清楚。我们最近阐明了一种新机制,其中CD69与其配体肌球蛋白轻链9、12a和12b(Myl9/12)之间的相互作用在将活化的T细胞募集到炎症性肺组织中起关键作用。在这篇综述中,我们首先基于其结构总结CD69的功能,然后介绍CD69参与人类疾病和小鼠疾病模型的证据。然后,我们将描述我们如何发现CD69配体Myl9和Myl12,以及CD69-Myl9系统如何调节气道炎症。最后,我们将讨论针对CD69-Myl9系统的阻断抗体可能的治疗用途。